Show simple item record

dc.contributor.advisorUribe Pérez, Claudia Janethspa
dc.contributor.authorBermúdez Flórez, Jorge Luisspa
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.coverage.temporal2008-2012spa
dc.date.accessioned2020-06-26T19:56:34Z
dc.date.available2020-06-26T19:56:34Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/20.500.12749/1687
dc.description.abstractEl carcinoma escamocelular es el segundo tumor maligno de piel más frecuente después del carcinoma basocelular pero, a diferencia de este último, con una mayor tasa de mortalidad y morbilidad dado por su mayor riesgo de metástasis, lo cual lo convierte en un problema de salud de importancia por los costos para el sistema de salud, los cuales pueden ser más altos que los observados a nivel mundial por las barreras en el acceso a la atención por el dermatólogo. Teniendo en cuenta la importancia de esta patología, se decide realizar este estudio retrospectivo con 727 pacientes tomando los datos del registro poblacional de cáncer del área metropolitana de Bucaramanga de los años 2008 a 2012, siendo el objetivo principal determinar la sobrevida a 5 años en esta población. Adicionalmente se determinara la tasa de incidencia del carcinoma escamocelular cutáneo, la caracterización de las variables sociodemográficas, clínicas e histopatológicas, mirando la asociación entre las variables histopatológicas y la sobrevida de los pacientes. Con los datos obtenidos en este estudio se encontró una tasa de incidencia cruda de 13,32 x100.000 personas – año, con una función de sobrevida general para el carcinoma escamocelular cutáneo en Bucaramanga de 64,55% y una función de sobrevida específica para el carcinoma escamocelular cutáneo en Bucaramanga de 98,21%; encontrando al estadio metastásico e invasión linfovascular como las variables asociadas con menor sobrevida, mientras que el grado moderadamente diferenciado se asoció con una mayor sobrevida. Se recomienda la implementación de un formato de reporte histopatológico con base a las recomendaciones de las guías del NCCN y la realización de un estudio posterior para verificar cambios en la sobrevida con la implementación de esta herramienta.spa
dc.description.tableofcontentsRESUMEN DEL PROYECTO .................................................................................................................. 8 1. JUSTIFICACIÓN: .............................................................................................................................. 9 2. MARCO TEÓRICO Y ESTADO DEL ARTE ............................................................................... 11 2.1. Definición: ...................................................................................................................................... 11 2.2. Epidemiología: ............................................................................................................................... 11 2.3. Factores Etiológicos: ..................................................................................................................... 13 2.4. Fisiopatología: ............................................................................................................................... 20 2.5. Manifestaciones Clínicas: ............................................................................................................. 21 2.5.1. Lesiones Precursoras: ............................................................................................................... 21 2.5.2. Lesiones In Situ (Enfermedad de Bowen):.............................................................................. 22 2.5.3. Lesiones Invasoras: ................................................................................................................... 23 2.6. Histopatología: .............................................................................................................................. 27 2.7. Diagnóstico Diferencial: ............................................................................................................... 31 2.8. Factores de riesgo para recurrencia local o Metástasis: ............................................................ 31 2.9. Estadificación del Carcinoma Escamocelular Cutáneo: ........................................................... 33 2.10. Tratamiento: .............................................................................................................................. 35 2.11. Pronóstico: ................................................................................................................................. 36 3. OBJETIVOS ...................................................................................................................................... 38 3.1. Objetivo General ....................................................................................................................... 38 3.2. Objetivos específicos ................................................................................................................. 38 3.3. Pregunta de Investigación ........................................................................................................ 38 4. METODOLOGÍA ............................................................................................................................. 39 4.1. Tipo de estudio: ......................................................................................................................... 39 4.2. Población: .................................................................................................................................. 39 4.3. Criterios de inclusión: ............................................................................................................... 39 4.4. Criterios de exclusión: .............................................................................................................. 39 4.5. Calculo de tamaño de muestra: ............................................................................................... 39 4.6. Muestreo: ................................................................................................................................... 40 4.7. Recolección de la información: ................................................................................................ 40 4.8. Variables: ................................................................................................................................... 40 4.9. Plan de análisis de datos: .......................................................................................................... 41 4.10. Consideraciones éticas: ......................................................................................................... 41 5. RESULTADOS: ................................................................................................................................ 43 5.1. Descripción de variables sociodemográficas: ............................................................................. 44 5.2. Descripción de variables clínicas: ................................................................................................ 48 5.3. Descripción de las Variables Histopatológicas: .......................................................................... 49 5.4. Análisis de sobrevida: ................................................................................................................... 53 5.4.1. Desenlace de casos de CSCc: .................................................................................................... 53 5.4.2. Análisis de sobrevida en general: ............................................................................................ 55 5.4.3. Análisis de Sobrevida por Variables Histopatológicas: ......................................................... 56 6. DISCUSIÓN: ..................................................................................................................................... 60 7. CONCLUSIONES: ........................................................................................................................... 65 8. REFERENCIAS BIBLIOGRÁFICAS: ........................................................................................... 66spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleSobrevida a 5 años de pacientes con carcinoma escamocelular de piel del área metropolitana de Bucaramanga entre los años 2008-2012spa
dc.title.translated5-year survival of patients with squamous cell carcinoma of the skin in the metropolitan area of ​​Bucaramanga between 2008-2012eng
dc.degree.nameEspecialista en Dermatologíaspa
dc.coveragespa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Dermatologíaspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsSquamous cell carcinomaeng
dc.subject.keywordsSkin diseaseseng
dc.subject.keywordsSurvivaleng
dc.subject.keywordsMedicineeng
dc.subject.keywordsDermatologyeng
dc.subject.keywordsInvestigationseng
dc.subject.keywordsAnalysiseng
dc.subject.keywordsCutaneous squamous cell carcinomaeng
dc.subject.keywordsSurvivaleng
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.relation.referencesBermúdez Flórez, Jorge Luis (2019). Supervivencia a 5 años de pacientes con carcinoma escamocelular de piel del área metropolitana de Bucaramanga entre los años 2008-2012. Bucaramanga (Colombia) : Universidad Autónoma de Bucaramanga UNABspa
dc.relation.references1. Mudigonda T, Pearce DJ, Yentzer BA, Williford P, Feldman SR, Dame N, et al. The Economic Impact of Non-Melanoma Skin Cancer : A Review. J Natl Compr Cancer Netw. 2010;8(8):888–96.spa
dc.relation.references2. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol [Internet]. 2013;68(6):957–66. Available from: http://dx.doi.org/10.1016/j.jaad.2012.11.037spa
dc.relation.references3. Domínguez-Cherit J, Rodríguez-Gutiérrez G, Narváez Rosales V, Toussaint Caire S, Fonte Avalos V. Characteristics and risk factors for recurrence of cutaneous squamous cell carcinoma with conventional surgery and surgery with delayed intraoperative margin assessment. Cir y Cir (English Ed [Internet]. 2016;(xx). Available from: http://dx.doi.org/10.1016/j.circir.2016.11.013spa
dc.relation.references4. Valeria Camila restrepo Arias, Hasbleidy Viviana Riaño Arévalo, Juan David Ríos Cerón, Beatriz Elvira Paz Córdoba JCC. Aspectos epidemiológicos del cáncer de piel diagnosticado en el año 2012 en 4 centros de referencia de Popayán , Colombia : un estudio observacional de corte transversal. Rev Colomb Cir plástica y Reconstr. 2016;22:36–43.spa
dc.relation.references5. Gordon R. Skin cancer: An overview of epidemiology and risk factors. Semin Oncol Nurs. 2013;29(3):160–9.spa
dc.relation.references6. Lim JL, Asgari M. Epidemiology and risk factors for cutaneous squamous cell carcinoma [Internet]. UpToDate. 2017. p. 1–17. Available from: www.uptodate.comspa
dc.relation.references7. Parekh V, Seykora JT. Cutaneous Squamous Cell Carcinoma. Clin Lab Med [Internet]. 2017;37(3):503–25. Available from: http://dx.doi.org/10.1016/j.cll.2017.06.003spa
dc.relation.references8. Rossi AM. Cutaneous Squamous Cell Carcinoma [Internet]. Dynamed. 2017. p. 1–36. Available from: http://insights.ovid.com/crossref?an=00125480-201707000-00001spa
dc.relation.references9. Lomas A, Bee L, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80.spa
dc.relation.references10. Nova J a. ., Sánchez G., Peña EB. Características epidemiológicas de pacientes con carcinoma escamocelular cutáneo en el Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia. Rev la Asoc Colomb Dermatología y Cirugía Dermatológica. 2011;19:212–7.spa
dc.relation.references11. Rees JR, Zens MS, Celaya MO, Riddle BL, Karagas MR, Peacock JL. Survival after squamous cell and basal cell carcinoma of the skin: A retrospective cohort analysis. Int J Cancer. 2015;137(4):878–84.spa
dc.relation.references12. Green AC, Olsen CM. Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol. 2017;177(2):373–81.spa
dc.relation.references13. Kauvar ANB, Arpey CJ, Hruza G, Olbricht SM, Bennett R. Consensus for Nonmelanoma 67 Skin Cancer Treatment, Part II. Dermatologic Surg [Internet]. 2015;41(11):1214–40. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00042728-201511000-00003spa
dc.relation.references14. Vallejo-Torres L, Morris S, Kinge J, Poirier V, Verne J. Measuring current and future cost of skin cancer in England. J Public Health (Bangkok). 2013;36(1):140–8.spa
dc.relation.references15. Doran CM, Ling R, Byrnes J, Crane M, Searles A, Perez D, et al. Estimating the economic costs of skin cancer in New South Wales , Australia. BMC Public Health [Internet]. 2015;15(952):1–10. Available from: http://dx.doi.org/10.1186/s12889-015-2267-3spa
dc.relation.references16. Gaviria Uribe A, Ruiz Gómez F, Muñoz Muñoz NJ, Burgos Bernal G OHJ. Guía de Práctica Clínica con evaluación económica para la prevención, diagnóstico, tratamiento y seguimiento del cáncer de piel no melanoma: carcinoma escamocelular de piel. Guias Pract Clínica Minsalud. 2014;(32):1–516.spa
dc.relation.references17. Burton KA, Ashack KA, Khachemoune A. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol. 2016;17(5):491–508.spa
dc.relation.references18. G.Sánchez JN. Factores de riesgo de carcinoma espinocelular , un estudio del Centro Nacional de Dermatología de Colombia. Actas dermosifiliográficas. 2013;104(8):672–8.spa
dc.relation.references19. Cheng J, Yan S. Prognostic variables in high-risk cutaneous squamous cell carcinoma: a review. J Cutan Pathol. 2016;43(11):994–1004.spa
dc.relation.references20. Nuño-González A, Vicente-Martín FJ, Pinedo-Moraleda F, López-Estebaranz JL. Carcinoma epidermoide cutáneo de alto riesgo. Actas Dermosifiliogr. 2012;103(7):567–78.spa
dc.relation.references21. Stratigos A, Garbe C, Lebbe C, Malvehy J, Del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007.spa
dc.relation.references22. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death. JAMA Dermatology [Internet]. 2016;152(4):419. Available from: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2015.4994spa
dc.relation.references23. Nova-Villanueva J, Sánchez-Vanegas G, Porras De Quintana L. Cáncer de Piel: Perfil Epidemiológico de un Centro de Referencia en Colombia 2003-2005. Rev Salud Pública. 2007;9(4):595–601.spa
dc.relation.references24. Gandhi SA, Kampp J. Skin Cancer Epidemiology, Detection, and Management. Med Clin North Am [Internet]. 2015;99(6):1323–35. Available from: http://dx.doi.org/10.1016/j.mcna.2015.06.002spa
dc.relation.references25. Cañueto J, Román-Curto C. Pronóstico y tratamiento del carcinoma epidermoide cutáneo. Piel [Internet]. 2017;1–14. Available from: http://linkinghub.elsevier.com/retrieve/pii/S021392511730062Xspa
dc.relation.references26. Uribe Pére CJ MDE. Incidencia de cáncer en el Área Metropolitana de Bucaramanga, 2000 - 2004. MedUNAB. 2007;10:147–72.spa
dc.relation.references27. Calonje E, Brenn T, Lazar A. Tumors of the surface epithelium [Internet]. Fourth Edi. Calonje E, editor. McKee’s Pathology of the Skin. Elsevier Inc; 2012. 1076-1149 p. Available from: http://www.crossref.org/deleted_DOI.htmlspa
dc.relation.references28. Kyrgidis A, Tzellos TG, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: Risk factors of overall and recurrence-free survival. Eur J Cancer [Internet]. 2010;46(9):1563–72. Available from: http://dx.doi.org/10.1016/j.ejca.2010.02.046spa
dc.relation.references29. Colegio, Oscar et al. Principles of Tumor Biology and Pathogenesis of BCCs and SCCs. In: Bolognia, Jean et al, editor. Dermatology. Fourth Edi. Elsevier Saunders; 2018. p. 1858–71.spa
dc.relation.references30. Kallini JR, Hamed N, Khachemoune A. Squamous cell carcinoma of the skin: Epidemiology, classification, management, and novel trends. Int J Dermatol. 2015;54(2):130–40.spa
dc.relation.references31. Grossman D. Carcinoma Escamocelular. In: Goldsmith LA, editor. Fitzpatrick Dermatologia en Medicina General. Octava Edi. Mc Graw Hill; 2012. p. 1310–56.spa
dc.relation.references32. Harwood CA, Toland AE, Proby CM, Euvrard S, Hofbauer GFL, Tommasino M, et al. The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol [Internet]. 2017;1–8. Available from: http://doi.wiley.com/10.1111/bjd.15956spa
dc.relation.references33. Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177(2):350–8.spa
dc.relation.references34. Soyer HP, Rigel DS, Mcmeniman E. Actinic Keratosis, Basal Cell Carcinoma, and Squamous Cell Carcinoma [Internet]. Fourth Edi. Bolognia, Jean et al, editor. Dermatology. Elsevier Ltd; 2017. 1872-1893 p. Available from: https://doi.org/10.1016/B978-0-7020-6275-9.00108-2spa
dc.relation.references35. Soyer HP, Rigel DS, Wurm EMT. Actinic Keratosis, Basal Cell Carcinoma and Squamous Cell Carcinoma [Internet]. Fourth Edi. Bolognia, Jean et al, editor. Dermatology, Third Edition. Elsevier Ltd; 2012. 1773-1793.e1 p. Available from: http://dx.doi.org/10.1016/B978-0-7234-3571-6.00108-1spa
dc.relation.references36. Deinlein T, Richtig G, Schwab C, Scarfi F, Arzberger E, Wolf I, et al. The use of dermatoscopy in diagnosis and therapy of nonmelanocytic skin cancer. JDDG J der Dtsch Dermatologischen Gesellschaft [Internet]. 2016;14(2):144–51. Available from: http://doi.wiley.com/10.1111/ddg.12903spa
dc.relation.references37. Zalaudek I, Giacomel J, Schmid K, Bondino S, Rosendahl C, Cavicchini S, et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: A progression model. J Am Acad Dermatol. 2012;66(4):589–97.spa
dc.relation.references38. Lim, Jean Lee, Asgari M. Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC) [Internet]. UpToDate. 2017. p. 1–22. Available from: www.uptodate.comspa
dc.relation.references39. Warszawik-Hendzel O, Olszewska M, Maj M, Rakowska A, Czuwara J, Rudnicka L. Non-invasive diagnostic techniques in the diagnosis of squamous cell carcinoma. J Dermatol Case Rep. 2015;9(4):89–97.spa
dc.relation.references40. Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol [Internet]. 2016;74(6):1220–33. Available from: http://dx.doi.org/10.1016/j.jaad.2015.11.033spa
dc.relation.references41. Christensen SR, McNiff JM, Cool AJ, Aasi SZ, Hanlon AM, Leffell DJ. Histopathologic assessment of depth of follicular invasion of squamous cell carcinoma (SCC) in situ (SCCis): Implications for treatment approach. J Am Acad Dermatol [Internet]. 2016;74(2):356–62. Available from: http://dx.doi.org/10.1016/j.jaad.2015.09.060spa
dc.relation.references42. K. C, Bichakjian. Squamous cell skin cancer [Internet]. www.nccn.org. 2017. p. 1–85. Available from: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdfspa
dc.relation.references43. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma. J Am Acad Dermatol [Internet]. 2018;78(2):237–47. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0190962217323253spa
dc.relation.references44. Aasi SZ. Treatment and prognosis of cutaneous squamous cell carcinoma [Internet]. UpToDate. 2017. p. 1–22. Available from: www.uptodate.comspa
dc.relation.references45. Karia PS, Schmults CD. Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma. UpToDate. 2018. p. 1–24.spa
dc.relation.references46. Robinson JK, Brockstein BE. Systemic treatment of advanced cutaneous squamous and basal cell carcinomas. Vol. 1, www.uptodate.com. 2018. p. 1–11.spa
dc.relation.references47. Stultz T. Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma. UpToDate. 2018. p. 1–15.spa
dc.relation.references48. Cernea SS, Pimentel ERDA, Tassara G, Fernandes VMC, Gontijo G, Tarlé RG, et al. Indication guidelines for Mohs micrographic surgery in skin tumors. An Bras Dermatol. 2016;91(5):621–7.spa
dc.relation.references49. Cormane J, Rodelo A. Epidemiología del cáncer no melanoma en Colombia Resumen. Rev Asoc Colomb Dermatología. 2014;1:20–6.spa
dc.relation.references50. Baquerizo K, Castro E, Muñoz S. Incidencia y características clínico patológicas del carcinoma espinocelular cutáneo. Hospital Nacional Alberto Sabogal Sologuren, 2004-2006. Folia dermatol [Internet]. 2007;18(2):63–71. Available from: http://sisbib.unmsm.edu.pe/bvrevistas/folia/vol18_n2/pdf/a02v18n2.pdfspa
dc.relation.references51. Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, Posada-García C, Rodríguez-Pazos L, Pastushenko I, et al. Incidencia y mortalidad del cáncer cutáneo en España: revisión sistemática y metaanálisis. Actas Dermosifiliogr [Internet]. 2016;107(4):318–28. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0001731016000089spa
dc.relation.references52. Hollestein LM, De Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: Increased incidence rates, but stable relative survival and mortality 1989-2008. Eur J Cancer [Internet]. 2012;48(13):2046–53. Available from: http://dx.doi.org/10.1016/j.ejca.2012.01.003spa
dc.relation.references53. Kyrgidis A, George T, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, et al. Cutaneous squamous cell carcinoma ( SCC ) of the head and neck : Risk factors of overall and recurrence-free survival. Eur J Cancer [Internet]. 2016;46(9):1563–72. Available from: http://dx.doi.org/10.1016/j.ejca.2010.02.046spa
dc.relation.references54. Sánchez G, Nova J. Factores de riesgo de carcinoma espinocelular, un estudio del Centro Nacional de Dermatología de Colombia. Actas Dermosifiliogr. 2013;104(8):672–8.spa
dc.relation.references55. Barton V, Armeson K, Hampras S, Ferris LK, Visvanathan K, Rollison D, et al. Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review. Arch Dermatol Res. 2017;309(4):243–51.spa
dc.relation.references56. Eigentler TK, Leiter U, Ha H, Garbe C, Ro M. Survival of Patients with Cutaneous Squamous Cell Carcinoma : Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137(July):2309–15.spa
dc.relation.references57. Peat B, Insull P AR. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2012;82(4):230–3.spa
dc.relation.references58. Reyes E, Uribe C, Vries E De. Population-based incidence and melanoma-specific survival of cutaneous malignant melanoma in a Colombian population 2000 – 2009. Int J Dermatol. 2017;1–7.spa
dc.relation.references59. Eigentler TK, Leiter U, Häfner H-M, Garbe C, Röcken M, Breuninger H. Survival of patients with cutaneous squamous cell carcinoma Results of a prospective cohort study. J Invest Dermatol [Internet]. 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022202X17318687spa
dc.relation.references60. Primeras causas de mortalidad general en Colombia desde 1980 a 2017. https://www.asivamosensalud.org/indicadores/comparativos-mortalidad-en-colombia/primeras-causas-de-mortalidad-general-en-colombia. 2017. p. 2.spa
dc.relation.references61. Yanofsky VR, Mercer SE, Phelps RG. Histopathological Variants of Cutaneous Squamous Cell Carcinoma: A Review. J Skin Cancer [Internet]. 2011;2011:1–13. Available from: http://www.hindawi.com/journals/jsc/2011/210813/spa
dc.relation.references62. Petter G, Haustein UF. Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. Dermatologic Surg. 2000;26(6):521–30.spa
dc.relation.references63. Pozzobon FC, Acosta AE, Castillo JS. Cáncer de piel en Colombia: Cifras del Instituto Nacional de Cancerología. Rev Asoc Colomb Dermatología. 2018;26(1):12–7.spa
dc.contributor.cvlachttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000267848*
dc.contributor.googlescholarhttps://scholar.google.es/citations?hl=es#user=hx8PM4AAAAAJ*
dc.contributor.orcidhttps://orcid.org/0000-0001-6972-921X*
dc.contributor.scopushttps://www.scopus.com/authid/detail.uri?authorId=55546023800*
dc.subject.lembCarcinoma escamocelularspa
dc.subject.lembEnfermedades de la pielspa
dc.subject.lembSupervivenciaspa
dc.subject.lembMedicinaspa
dc.subject.lembDermatologíaspa
dc.subject.lembInvestigacionesspa
dc.subject.lembAnálisisspa
dc.description.abstractenglishSquamous cell carcinoma is the second most common malignant skin tumor after basal cell carcinoma but, unlike the latter, with a higher mortality and morbidity rate due to its higher risk of metastasis, which makes it a health problem for importance due to the costs for the health system, which may be higher than those observed worldwide due to the barriers in access to care by the dermatologist. Taking into account the importance of this pathology, it was decided to carry out this retrospective study with 727 patients, taking data from the population registry of cancer of the metropolitan area of ​​Bucaramanga from 2008 to 2012, the main objective being to determine the 5-year survival in this population. Additionally, the incidence rate of cutaneous squamous cell carcinoma will be determined, as well as the characterization of the sociodemographic, clinical and histopathological variables, looking at the association between the histopathological variables and the survival of the patients. With the data obtained in this study, a crude incidence rate of 13.32 x 100,000 person-years was found, with a general survival function for cutaneous squamous cell carcinoma in Bucaramanga of 64.55% and a specific survival function for cutaneous squamous cell carcinoma in Bucaramanga of 98.21%; finding the metastatic stage and lymphovascular invasion as the variables associated with lower survival, while the moderately differentiated degree was associated with higher survival. The implementation of a histopathological report format is recommended based on the recommendations of the NCCN guidelines and the performance of a subsequent study to verify changes in survival with the implementation of this tool.eng
dc.subject.proposalCarcinoma escamocelular cutáneo
dc.subject.proposalSupervivencia
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 2.5 Colombia